AUROPHARMA Aurobindo Pharma Q1 FY27 results (Apr–Jun 2026) and concall
Aurobindo Pharma reported a strong Q1 FY27 with consolidated revenues up 16% YoY to Rs. 9,150 crores and an Operating EBITDA margin of 21%. The quarter was highlighted by the successful Lannett acquisition, which is set to bolster the US business. The company reiterated its FY27 guidance for double-digit revenue growth and EBITDA margins north of 21%, underpinned by strategic investments in biosimilars, complex generics, and capacity expansion. R&D spend is expected to be Rs. 1,450-1,500 crores for FY27, with a focus shifting from clinical studies to filings and implementation.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue up 16.3%, net profit up 25.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 +6% | 8,646 +8% | 8,853 +6% | 9,150 +16% |
| EBITDA | 1,566 | 1,578 | 1,760 | 1,603 | 1,678 +7% | 1,773 +12% | 1,750 −1% | 1,880 +17% |
| Net profit | 817 | 846 | 903 | 824 | 848 +4% | 910 +8% | 921 +2% | 1,032 +25% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
